Cancer stem cell-related marker NANOG expression in ovarian serous tumors using Western blotting and immunohistochemistry: comparison of two techniques

Purpose of Investigation: The objective of the study was to evaluate cancer stem cell-related marker NANOG expression in ovarian serous tumors using Western blotting (WB) and to compare WB results to immunohistochemical (IHC) results of NANOG expression in the same tumors. Materials and Methods: Of the 37 ovarian tumor samples obtained intraoperatively, diagnosis of ovarian serous tu-mors was established histopathologically in 17 cases. WB and IHC for NANOG was performed on the parallel portions of the same ovarian tumors in the latter cases. The IHC staining samples were made up of a NANOG positive and a NANOG-negative group. Pur-suant to summation of signal intensity and positive cell occurrence, the authors additionally divided the NANOG-positive group into three subgroups. Correlation coefficient between NANOG WB and NANOG IHC results was calculated. Results: NANOG measured by means of WB was significantly higher in the IHC determined NANOG-positive group than in the NANOG-negative group (p = 0.003). Comparison of the amount of NANOG measured by WB and IHC scores of individual cases revealed substantial dispersion of WB results among the NANOG subgroups; the dispersion was largest when NANOG was IHC only slightly-positive. In the NANOG moderate- and strongly-positive subgroups, WB values were higher and more homogenously arranged. In all IHC determined NANOG-negative cases NANOG WB values were low, with low value variability among tumor samples. However, correlation between NANOG WB results and NANOG IHC scoring subgroups revealed statistical significance (r = 0.73, p = 0.001). Conclusion: By means of WB and IHC the authors demonstrated NANOG to be a potential marker of ovarian high-grade serous carcinoma. Further research on the correlation between NANOG WB expression and clinical parameters is needed.

Ovarian cancer; Cancer stem cell-related marker; NANOG; Western blotting; Immunohistochemistry.

[1] Virant-Klun I., Skutella T., Cvjeticanin B., Stimpfel M., Sinkovec J.: “Serous papillary adenocarcinoma possibly related to the presence of primitive oocyte-like cells in the adult ovarian surface epithelium: a case report”. J. Ovarian Res., 2011, 4, 13.

[2] Wang J., Rao S., Chu J., Shen X., Levasseur D.N., Theunissen T.W., Orkin S.H.: “A protein interaction network for pluripotency of em-bryonic stem cells”. Nature, 2006, 444, 364.

[3] Chambers I., Colby D., Robertson M., Nichols J., Lee S., Tweedie S., Smith A.: “Functional expression cloning of Nanog, a pluripo-tency sustaining factor in embryonic stem cells”. Cell, 2003, 113, 643.

[4] Kashyap V., Rezende N.C., Scotland K.B., Shaffer S.M., Persson J. L., Gudas L.J., Mongan N.P.: “Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs”. Stem Cells Dev., 2009, 18, 1093.

[5] Bourguignon L.Y., Peyrollier K., Xia W., Gilad E.: “Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells”. J. Biol. Chem., 2008, 283, 17635.

[6] Hart A.H., Hartley L., Parker K., Ibrahim M., Looijenga L.H., Pauch-nik M., et al.:” The pluripotency homeobox gene NANOG is ex-pressed in human germ cell tumors”. Cancer, 2005, 104, 2092.

[7] Ezeh U.I., Turek P.J., Reijo R.A., Clark A.T.: “Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are ex-pressed in both seminoma and breast carcinoma”. Cancer, 2005, 104, 2255.

[8 Hoei-Hansen C.E., Almstrup K., Nielsen J.E., Brask Sonne S., Graem N., Skakkebaek N.E., et al.: “Stem cell pluripotency factor NANOG is expressed in human fetal gonocytes, testicular carcinoma in situ and germ cell tumours”. Histopathology, 2005, 47, 48.

[9] Pan Y., Jiao J., Zhou C., Cheng Q., Hu Y., Chen H.: “Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade”. Pathobiology, 2010, 77, 283.

[10] Lee M., Nam E.J., Kim S.W., Kim S., Kim J.H., Kim Y.T.: “Prog-nostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma”. Int. J. Gynecol. Cancer, 2012, 22, 1489.

[11] Siu M.K., Wong E.S., Kong D.S., Chan H.Y., Jiang L., Wong O.G., et al.: “Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and con-tributes to adverse clinical outcome in ovarian cancers“. Oncogene, 2013, 32, 3500.

[12] Kenda Suster N., Frkovic Grazio S., Virant-Klun I., Verdenik I., Sm-rkolj S.: “Cancer Stem Cell-Related Marker NANOG Expression in Ovarian Serous Tumors: A Clinicopathological Study of 159 Cases”. Int. J. Gynecol. Cancer, 2017, 27, 2006.

[13] Towbin H., Staehelin T., Gordon J.: “Electrophoretic transfer of pro-teins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications”. Biotechnology, 1992, 24, 145.

[14] Kurman R.J., Carcangiu M.L., Herrington C.S., Young R.H., (ed.). WHO classification of tumours of female reproductive organs. Lyon: International Agency for Research on Cancer, 2014.

[15] Wittekind C., Compton C.C., Greene F.L., Sobin L.H.:” TNM resid-ual tumor classification revisited”. Cancer, 2002, 94, 2511.

[16] Cao J., Meng F.J., Li L., Lu C., Zhou J., Cheng H., et al.: “Expression of NANOG gene in acute lymphoblastic leukemia cells and construc-tion of lentiviral vector carrying NANOG specific shRNA”. Zhong-guo Shi Yan Xue Ye Xue Za Zhi, 2014, 22, 275.

[17] Wang H., Liu B., Wang J., Li J., Gong Y., Li S., et al.: “Reduction of NANOG Mediates the Inhibitory Effect of Aspirin on Tumor Growth and Stemness in Colorectal Cancer”. Cell Physiol. Biochem., 2017, 44, 1051.

[18] Luo H., Li Q., Pramanik J., Luo J., Guo Z.: “Nanog expression in heart tissues induced by acute myocardial infarction”. Histol. Histopathol., 2014, 29, 1287.

[19] Xiao L., Song Y., Huang W., Yang S., Fu J., Feng X., Zhou M.: “Ex-pression of SOX2, NANOG and OCT4 in a mouse model of lipopolysaccharide-induced acute uterine injury and intrauterine ad-hesions”. Reprod. Biol. Endocrinol., 2017, 15 ,14.

[20] Song Y., Xiao L., Fu J., Huang W., Wang Q., Zhang X., Yang S.: “In-creased expression of the pluripotency markers sex-determining re-gion Y-box 2 and Nanog homeobox in ovarian endometriosis”. Reprod. Biol. Endocrino., 2014, 12, 42.

[21] Torlakovic E.E., Nielsen S., Vyberg M., Taylor C.R.: “Getting con-trols under control: the time is now for immunohistochemistry”. J. Clin. Pathol., 2015, 68, 879.

[22] Do H.J., Lim H.Y., Kim J.H., Song H., Chung H.M., Kim J.H.: “An intact homeobox domain is required for complete nuclear localiza-tion of human Nanog”. Biochem. Biophys. Res. Commun,. 2007, 353, 770.

[23] Park I.H., Zhao R., West J.A., Yabuuchi A., Huo H., Ince T.A., et al.: “Reprogramming of human somatic cells to pluripotency with de-fined factors”. Nature, 2008, 451, 141.

[24] Ye F., Zhou C., Cheng Q., Shen J., Chen H.: “Stem-cell-abundant proteins Nanog, Nucleostemin and Musashi1 are highly expressed in malignant cervical epithelial cells”. BMC Cancer, 2008, 8, 108.